BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy

Clinical trials are currently exploring combinations of PARP inhibitors and immunotherapies for the treatment of ovarian cancer, but their effects on the ovarian tumour microenvironment (TME) remain unclear. Here, we investigate how olaparib, PD-L1 monoclonal antibodies, and their combination can in...

Descripción completa

Detalles Bibliográficos
Autores principales: Farokhi Boroujeni, Salar, Rodriguez, Galaxia, Galpin, Kristianne, Yakubovich, Edward, Murshed, Humaira, Ibrahim, Dalia, Asif, Sara, Vanderhyden, Barbara C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683289/
https://www.ncbi.nlm.nih.gov/pubmed/38017453
http://dx.doi.org/10.1186/s13048-023-01313-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683289/
https://www.ncbi.nlm.nih.gov/pubmed/38017453
http://dx.doi.org/10.1186/s13048-023-01313-z

Ejemplares similares